- Home
- BMN vs BDTX Comparison
BMN vs BDTX Comparison
Compare BMN & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMN | BDTX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.0M | 171.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BMN | BDTX |
|---|---|---|
| Price | $25.00 | $1.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 5.6K | ★ 1.6M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.96 | $1.60 |
| 52 Week High | $27.96 | $4.94 |
Technical Indicators
Market Signals| Indicator | BMN | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 34.64 | 42.31 |
| Support Level | $24.49 | $1.76 |
| Resistance Level | $25.19 | $2.26 |
| Average True Range (ATR) | 0.19 | 0.11 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 0.00 | 6.17 |
Price Performance
Historical ComparisonAbout BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.